이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Panbela Therapeutics 관리

관리 기준 확인 3/4

Panbela Therapeutics' CEO는 Jennifer Simpson, Jul2020 에 임명되었습니다 의 임기는 2.75 년입니다. 총 연간 보상은 $ 694.32K, 72.9% 로 구성됩니다. 72.9% 급여 및 27.1% 보너스(회사 주식 및 옵션 포함). 는 € 2.34K 가치에 해당하는 회사 주식의 0.031% 직접 소유합니다. 2.34K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.3 년입니다.

주요 정보

Jennifer Simpson

최고 경영자

US$694.3k

총 보상

CEO 급여 비율	72.9%
CEO 임기	2.8yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jennifer Simpson 의 보수는 Panbela Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2022	US$694k	US$506k	-US$35m
Sep 30 2022	n/a	n/a	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$1m	US$477k	-US$10m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$2m	US$146k	-US$5m

보상 대 시장: Jennifer 의 총 보상 ($USD 694.32K )은 German 시장( $USD 434.78K ).

보상과 수익: Jennifer 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jennifer Simpson (54 yo)

2.8yrs

테뉴어

US$694,324

보상

Dr. Jennifer K. Simpson, Ph D., M.S.N., C.R.N.P. has been the Chief Executive Officer, President and Director of Panbela Therapeutics, Inc. (formerly known as Sun BioPharma, Inc.) since July 15, 2020. She...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jennifer Simpson	CEO, President & Director	2.8yrs	US$694.32k	0.031% $ 2.3k
Susan Horvath	VP of Finance	5yrs	US$423.46k	0.033% $ 2.5k
Tammy Groene	Vice President of Operations	no data	데이터 없음	데이터 없음
Elizabeth Bruckheimer	VP & Chief Scientific Officer	less than a year	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

경험이 풍부한 관리: X70 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jennifer Simpson	CEO, President & Director	2.8yrs	US$694.32k	0.031% $ 2.3k
Jeffrey Mathiesen	Vice Chair & Lead Independent Director	7.6yrs	US$81.50k	0.0018% $ 131.9
Michael Cullen	Chairman	7.6yrs	US$72.50k	0.10% $ 7.6k
Jeffrey Jacob	Director	less than a year	US$20.00k	0.063% $ 4.7k
Daniel Donovan	Independent Director	less than a year	US$26.25k	0.053% $ 4.0k
Arthur Fratamico	Independent Director	3.3yrs	US$49.00k	0.0016% $ 121.4
Donald Schemel	Independent Director	7.6yrs	US$57.50k	0.10% $ 7.6k
Tanios Bekaii-Saab	Scientific Advisor	no data	데이터 없음	데이터 없음
Andrew Ko	Scientific Advisor	no data	데이터 없음	데이터 없음
Dusan Kotasek	Scientific Advisor	no data	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: X70 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Panbela Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Recent updates

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. Announces Nasdaq Files A Form 25 Notification of Removal from Listing

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025

Panbela Announces Poster Presentation At American Association for Cancer Research

Panbela Therapeutics, Inc. has filed a Follow-on Equity Offering.

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령